CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Arthur Klausner to speak at Biotech & Life Science Global Venture Congress 2006 in New York City
News | 09. 14. 2006
